Program

Keynote Address

7:00 p.m.-8:00 p.m.

Inflammation and cancer: Interweaving microRNA free radicals, inflammatory cytokines, and p53 networks
Curtis C. Harris, National Cancer Institute, Bethesda, MD

Networking Reception

8:00 p.m.-9:30 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 1: Infection, Inflammation, and Cancer

Chairperson: James G. Fox, Massachusetts Institute of Technology, Cambridge, MA
8:00 a.m.-10:00 a.m.

Helicobacter-associated chronic inflammation and gastrointestinal cancers
James G. Fox

Gastric cancer: An infectious disease
Pelayo Correa, Vanderbilt University Medical Center, Nashville, TN

Hepatitis B viral mutations and inflammation in liver cancer
John D. Groopman, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

Mechanisms of inflammasome activation in asbestos-associated mesothelioma
Brooke T. Mossman, University of Vermont College of Medicine, Burlington, VT

Break

10:00 a.m.-10:30 a.m.

Minisymposium I

10:30 a.m.-11:30 a.m.
Presentations from proffered abstracts and late-breaking papers

Inflammation in TGFβ-mediated carcinogenesis
B.R. Achyut, National Cancer Institute, Bethesda, MD

Tumor-recruited inflammatory neutrophils and their TIMP-free MMP-9 determine coordinately the levels of tumor angiogenesis and malignant cell dissemination
Elena I. Deryugina, The Scripps Research Institute, La Jolla, CA

Signal integration from PI 3-kinases and phospholipase D regulates proinflammatory NADPH oxidase activity and extracellular reactive oxygen species production
Christian D. Ellson, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

Oxidative stress as a target for drug development in prostate cancer
Athanasios Paschos, McMaster University and Juravinski Cancer Center, Hamilton, ON, Canada

Lunch on own / Optional Professional Advancement Session

11:30 a.m.-1:30 p.m.

Session 2: Chemical Mediators of Inflammation I

Chairperson: David A. Wink, National Cancer Institute, Bethesda, MD
1:30 p.m.-3:30 p.m.

Nitric oxide, inflammation, and cancer
David A. Wink

Macrophage pathways for oxidative damage in humans
Jay W. Heinecke, University of Washington School of Medicine, Seattle, WA

Production and reactions of oxidants produced by myeloperoxidase
Christine Winterbourn, University of Otago, Christchurch, New Zealand

Neutrophil-mediated DNA damage
Lawrence C. Sowers, Loma Linda University, Loma Linda, CA

Break

3:30 p.m.-4:00 p.m.

Minisymposium II

4:00 p.m.-5:00 p.m.
Presentations from proffered abstracts and late-breaking papers

RNA editing changes the lesion specificity for the DNA repair enzyme NEIL1
Sheila S. David, University of California, Davis, CA

Environmentally induced oxidative stress: TCDD- and benzo[a]pyrene-mediated arachidonic acid metabolism in H358 human lung cells
Stacy Lynn Gelhaus, University of Pennsylvania, Philadelphia, PA

Inflammation-induced DNA glycation: A potential role in TNF-α-mediated response mechanisms
John Termini, City of Hope, Duarte, CA

The metabolism and signaling of the lipid peroxidation product 4-HNE
Gregory P. Tochtrop, Case Western Reserve University, Cleveland, OH

Poster Session A and Reception

5:00 p.m.-7:00 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 3: Chemical Mediators of Inflammation II

Chairperson: Cynthia J. Burrows, University of Utah, Salt Lake City, UT
8:00 a.m.–10:00 a.m.

Beyond 8-oxoG: Chemistry and biochemistry of hyperoxidized guanine
Cynthia Burrows

AGEs, inflammation, and cancer in diabetes
John W. Baynes, University of South Carolina, Columbia, SC

Redox regulation of Ras superfamily GTPases
Sharon Campbell, University of North Carolina, Chapel Hill, NC

Reaction pathways of radicals formed by the oxidation of guanine in DNA by peroxynitrite-derived reactive intermediates and characterization of the end products
Nicholas E. Geacintov, New York University, New York, NY

Break

10:00 a.m.-10:30 a.m.

Minisymposium III

10:30 a.m.-11:30 a.m.
Presentations from proffered abstracts and late-breaking papers

Nitrogen-oxide-releasing NSAIDs as anticancer agents
Katrina M. Miranda, University of Arizona, Tucson, AZ

Caged nitric oxide prodrugs for cancer therapy
Larry K. Keefer, National Cancer Institute at Frederick, Frederick, MD

Organ- and lesion-dependent biases in the spectrum of inflammation-induced DNA damage in colon and liver from Helicobacter hepaticus-infected Rag2-deficient mice
Aswin Mangerich, Massachusetts Institute of Technology, Cambridge, MA

COX-2 inhibitors in PET imaging of inflammation and cancer
Jashim Uddin, Vanderbilt University, Nashville, TN

Poster Session B and Lunch

11:30 a.m.-1:30 p.m.

Session 4: Biomarkers of Inflammation

Chairperson: Steven R. Tannenbaum, Massachusetts Institute of Technology, Cambridge, MA
1:45 p.m.–3:45 p.m.

Complex biomarker sets for inflammatory bowel disease
Steven R. Tannenbaum

Nucleic acid modifications as biomarkers of inflammation
Peter C. Dedon, Massachusetts Institute of Technology, Cambridge, MA

Lipid oxidation and inflammation
Ian A. Blair, University of Pennsylvania School of Medicine, Philadelphia, PA

Electrophile-protein adducts as triggers for inflammation-related stress responses
Daniel C. Liebler, Vanderbilt University, Nashville, TN

Break

3:45 p.m.-4:15 p.m.

Minisymposium IV

4:15 p.m.-5:15 p.m.
Presentations from proffered abstracts and late-breaking papers

A novel mPGES-1 inhibitor with antitumor activity
Hui-Hua Chang, University of Arizona, Tucson, AZ

In vivo imaging of cancer therapy with glucocorticoid-loaded nanoparticles in an experimental model
Anita Gianella, Mount Sinai School of Medicine, New York, NY

Novel celecoxib derivatives that inhibit growth in MCF-7 human breast cancer cell line
Leyte L. Winfield, Spelman College, Atlanta, GA

Design of second-generation silicon derivatives of indomethacin as inhibitors of inflammation and tumor growth: Iterative chemical design in pursuit of optimal bioactivity
Uzma I. Zakai, University of Wisconsin, Madison, WI

Evening off / Dinner on own

5:15 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Session 5: Systems Biology of Inflammation

Chairperson: Forest M. White, Massachusetts Institute of Technology, Cambridge, MA
8:00 a.m.-10:00 a.m.

Biological insights from quantitative analysis of tyrosine kinase signaling networks
Forest White

Inflammation in human prostate carcinogenesis: An etiological factor triggering somatic epigenome defects in prostate cancer
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

Systematic functional genomics and cancer
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Role of pregnane X receptor (PXR) in colon carcinogenesis
Frank J. Gonzalez, National Cancer Institute, Bethesda, MD

Break

10:00 a.m.-10:30 a.m.

Session 6: Chemoprevention and Drug Development

Chairperson: Lawrence J. Marnett, Vanderbilt University Medical Center, Nashville, TN
10:30 a.m.-12:30 p.m.

Substrate-selective inhibition of endocannabinoid oxygenation by cyclooxygenase-2
Lawrence J. Marnett

Natural products as leads for cancer therapy: Triptolide and phenanthropiperidines
Gunda I. Georg, University of Minnesota College of Pharmacy, Minneapolis, MN

Development of ipilimumab: Lessons learned
Ramy Ibrahim, Bristol-Myers Squibb Co., Wallingford, CT

Restoring the immune response to cancers by inhibition of IDO
Andrew P. Combs, Incyte Corporation, Kennett Square, PA

Departure